UNVEILING THE DARK SIDE OF CLINICAL TRIALS
Raghavendra Rao M.V, Sumana Sen, G. Pavani, A. Rekha, Sindhuja Rangisetty, G. Anantha Lakshmi, RajKumar. Kudari, Mahendra Kumar Verma- General Medicine
- General Medicine
- Education
- Political Science and International Relations
- Public Administration
- Social Sciences (miscellaneous)
- Social Sciences (miscellaneous)
- Sociology and Political Science
- General Economics, Econometrics and Finance
- General Business, Management and Accounting
- Management of Technology and Innovation
- Strategy and Management
- Development
- Business and International Management
- Electrochemistry
- Spectroscopy
- Toxicology
- Analytical Chemistry
- General Materials Science
- Agricultural and Biological Sciences (miscellaneous)
- Applied Microbiology and Biotechnology
- Ecology, Evolution, Behavior and Systematics
- Biotechnology
There is an old saying-“public health is public wealth”.The evolution of drug discovery traverses a long and fascinating journey.The security of drugs is pivotal because no drug is absolutely safe for all people,in all places,at all times.In the last few decades,biomedical research has grown tremendously and the use of animals has also increased as a research model for clinical trials.Clinical trials are crucial for identifying novel disease treatments as well as innovative methods of disease detection,diagnosis, and risk reduction.Researchers can learn things about what works and doesn't work in humans through clinical trials that cannot be discovered through laboratory or animal testing.Biomedical research also assists medical professionals in determining whether a novel treatment's adverse effects are tolerable in comparison to its potential benefits.There should be strong reasons based on laboratory,animal,and human trials if greater doses are to be examined. But there would also be a higher chance of adverse outcomes. Management of Drug Disasters among the human population remains a major therapeutic challenge throughout the world.